Beyond GLP-1s: Peptide Strategies for Fat Loss and Muscle Preservation

When people think of "peptides for weight loss" lately, they immediately go to GLP-1 agonists (like Semaglutide). However, those often come with the side effect of "gastroparesis" or slowed motility—the exact opposite of what you’re looking for.

To suppress appetite gently while keeping the "engines running" (motility) and prioritizing body composition, we look toward the Growth Hormone Secretagogue (GHS) family and specific Lipolytic Fragments.

Here is a summary of the top candidates that balance fat loss with muscle preservation:

1. Tesamorelin

Originally developed to treat lipodystrophy, Tesamorelin is widely considered the "gold standard" for visceral fat loss without the heavy GI suppression seen in other metabolic drugs.

• Mechanism of Action: It is a stabilized analogue of Growth Hormone-Releasing Hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating the pulsatile release of endogenous Growth Hormone (GH).
• Impact on Fat & Muscle: Increased GH levels elevate IGF-1 (Insulin-like Growth Factor 1), which promotes protein synthesis (muscle) and stimulates lipolysis (fat breakdown), particularly in the abdominal region.
• Motility & Appetite: Unlike GLP-1s, it does not slow gastric emptying. Its appetite suppression is "gentle" and secondary—derived from improved insulin sensitivity and metabolic efficiency rather than nausea or fullness.

2. Ipamorelin

If you’re looking for "gentle," Ipamorelin is the most sophisticated choice. It is a selective GH secretagogue that lacks the harsh side effects of older generations.

• Mechanism of Action: It mimics ghrelin by binding to the Growth Hormone Secretagogue Receptor (GHSR). However, unlike its predecessor (GHRP-6), it is highly selective. It stimulates GH release without significantly spiking cortisol, prolactin, or—crucially—extreme hunger.
• Impact on Fat & Muscle: By increasing GH pulses, it aids in nitrogen retention and muscle recovery while signaling the body to use stored fat for fuel.
• Motility & Appetite: Because it targets ghrelin receptors, it can actually support gastric motility (prokinetic effect) rather than suppressing it. It offers a subtle "metabolic tightening" of appetite rather than a total shutdown.

3. AOD9604 (Anti-Obesity Drug)

This is a small fragment of the C-terminus of the human Growth Hormone molecule (amino acids 177–191).

• Mechanism of Action: It is designed specifically to trigger lipolysis (fat burning) and inhibit lipogenesis (the transformation of non-fatty foods into body fat). It does this without affecting the GHRH receptor, meaning it doesn't impact IGF-1 levels or blood sugar.
• Impact on Fat & Muscle: It is purely a fat-burner. While it doesn't "build" muscle directly like Tesamorelin, it preserves it by ensuring the body has an abundant supply of free fatty acids to use for energy, sparing muscle protein.
• Motility & Appetite: It has no known effect on the digestive tract or the "fullness" centers of the brain. It is a "behind-the-scenes" metabolic enhancer.

4. CJC-1295 (Without DAC)

Often paired with Ipamorelin, this peptide acts as a long-acting GHRH mimetic.

• Mechanism of Action: It extends the "pulse" of growth hormone. When used "without DAC" (Drug Affinity Complex), it mimics a more natural physiological release.
• Impact on Fat & Muscle: It works synergistically with GHS peptides to keep the body in an anabolic (building) state for muscle and a catabolic (breaking down) state for fat.
• Motility & Appetite: It generally has a neutral effect on the gut. Any appetite suppression is usually the result of the body becoming more efficient at utilizing its own energy stores.

Comparative Summary Table

A Note on Strategy

The most common "gentle" protocol often involves a combination of CJC-1295 + Ipamorelin. This duo provides a steady increase in growth hormone that favors a "leaner" look and better recovery without the "gut-stop" or "brain-fog" associated with more aggressive weight-loss medications.

Most Growth Hormone Secretagogues (GHS) and GHRH analogs—specifically Ipamorelin, CJC-1295, and Tesamorelin—require an empty stomach to be effective.

The primary reason is the relationship between insulin, blood glucose, and Growth Hormone (GH) release.

The "Empty Stomach" Rule

To maximize the pulsatile release of GH, you generally need to be in a fasted state (at least 2–3 hours after your last meal and 30–60 minutes before your next).

1. Ipamorelin & CJC-1295 (The Combo)

• Requirement: Strictly empty stomach.
• The Science: These peptides trigger the pituitary gland to release GH. However, insulin (secreted after eating carbohydrates) and somatostatin (which increases after eating) are "GH-inhibitors." If you have elevated insulin or blood glucose levels when you administer these, the GH pulse will be significantly blunted or neutralized.
• Protocol: Most users administer these right before bed or first thing in the morning to capitalize on naturally low insulin levels.

2. Tesamorelin

• Requirement: Empty stomach (usually evening).
• The Science: Similar to CJC-1295, Tesamorelin is a GHRH analog. Since its clinical purpose is reducing deep visceral fat, you want the resulting GH spike to occur when the body is in a "fat-burning" (fasted) state. Eating before administration triggers an insulin response that competes with the lipolytic (fat-clearing) effects of the peptide.

3. AOD9604

• Requirement: Fasted state.
• The Science: While AOD9604 does not trigger a GH pulse (and thus isn't as sensitive to the insulin/somatostatin loop), it is most effective when there is no competing fuel source in the bloodstream. By taking it while fasted—often before morning cardio—you force the body to utilize the fatty acids mobilized by the peptide for energy.

Summary of Timing